Related references
Note: Only part of the references are listed.Lumateperone: A Novel Antipsychotic for Schizophrenia
Jessica Greenwood et al.
ANNALS OF PHARMACOTHERAPY (2021)
Toward dynamic phenotypes and the scalable measurement of human behavior
Laura Germine et al.
NEUROPSYCHOPHARMACOLOGY (2021)
Biotyping in psychosis: using multiple computational approaches with one data set
Carol A. Tamminga et al.
NEUROPSYCHOPHARMACOLOGY (2021)
Big data in psychiatry: multiomics, neuroimaging, computational modeling, and digital phenotyping
Kerry J. Ressler et al.
NEUROPSYCHOPHARMACOLOGY (2021)
Innovative screening models for the discovery of new schizophrenia drug therapies: an integrated approach
Marinos G. Sotiropoulos et al.
EXPERT OPINION ON DRUG DISCOVERY (2021)
The clinical characterization of the patient with primary psychosis aimed at personalization of management
Mario Maj et al.
WORLD PSYCHIATRY (2021)
A Neurodevelopment Approach for a Transitional Model of Early Onset Schizophrenia
Domenico De Berardis et al.
BRAIN SCIENCES (2021)
Real-World Data on the Adverse Metabolic Effects of Second-Generation Antipsychotics and Their Potential Determinants in Adult Patients: A Systematic Review of Population-Based Studies
Miquel Bernardo et al.
ADVANCES IN THERAPY (2021)
Beyond Dopamine Receptor Antagonism: New Targets for Schizophrenia Treatment and Prevention
Felipe V. Gomes et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Augmentation With Pimavanserin in Treatment Refractory Schizophrenia Case Report
Jean-Pierre Lindenmayer et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2021)
Schizophrenia outcomes in the 21st century: A systematic review
Peter Huxley et al.
BRAIN AND BEHAVIOR (2021)
Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety
Istvan Laszlovszky et al.
ADVANCES IN THERAPY (2021)
Long-term Continuity of Antipsychotic Treatment for Schizophrenia: A Nationwide Study
Jose M. Rubio et al.
SCHIZOPHRENIA BULLETIN (2021)
Enhancing Prediction of Psychosis Risk With Cognitive Measures How Do We Get to There From Here?
James M. Gold et al.
JAMA PSYCHIATRY (2021)
Neurocognitive Functioning in Individuals at Clinical High Risk for Psychosis A Systematic Review and Meta-analysis
Ana Catalan et al.
JAMA PSYCHIATRY (2021)
Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
Christoph U. Correll et al.
CNS DRUGS (2021)
A dopaminergic mechanism of antipsychotic drug efficacy, failure, and failure reversal: the role of the dopamine transporter
Davide Amato et al.
MOLECULAR PSYCHIATRY (2020)
Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology
Stephen J. Kaar et al.
NEUROPHARMACOLOGY (2020)
In the aftermath of clozapine discontinuation: comparative effectiveness and safety of antipsychotics in patients with schizophrenia who discontinue clozapine
Jurjen J. Luykx et al.
BRITISH JOURNAL OF PSYCHIATRY (2020)
Newer Formulations of Risperidone: Role in the Management of Psychotic Disorders
Ivana Clark et al.
CNS DRUGS (2020)
Nose-to-brain delivery of antipsychotics using nanotechnology: a review
Madeleine S. A. Tan et al.
EXPERT OPINION ON DRUG DELIVERY (2020)
Identification of a Serotonin 2A Receptor Subtype of Schizophrenia Spectrum Disorders With Pimavanserin: The Sub-Sero Proof-of-Concept Trial Protocol
Olga B. Baltzersen et al.
FRONTIERS IN PHARMACOLOGY (2020)
A Non-D2-Receptor-Binding Drug for the Treatment of Schizophrenia
Kenneth S. Koblan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Promising Evidence of Antipsychotic Efficacy without Dopamine D2-Receptor Binding
Donald C. Goff
NEW ENGLAND JOURNAL OF MEDICINE (2020)
A systematic review and narrative synthesis of data-driven studies in schizophrenia symptoms and cognitive deficits
Tesfa Dejenie Habtewold et al.
TRANSLATIONAL PSYCHIATRY (2020)
A review of negative symptom assessment strategies in youth at clinical high-risk for psychosis
Gregory P. Strauss et al.
SCHIZOPHRENIA RESEARCH (2020)
Pathophysiology of negative symptom dimensions of schizophrenia - Current developments and implications for treatment
Indrit Begue et al.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2020)
Cognition, Social Cognition, and Functional Capacity in Early-Onset Schizophrenia
Philip D. Harvey et al.
CHILD AND ADOLESCENT PSYCHIATRIC CLINICS OF NORTH AMERICA (2020)
Neurodevelopmental Factors in Schizophrenia
Hanna Jaaro-Peled et al.
PSYCHIATRIC CLINICS OF NORTH AMERICA (2020)
Negative Symptoms in Schizophrenia: A Review and Clinical Guide for Recognition, Assessment, and Treatment
Christoph U. Correll et al.
NEUROPSYCHIATRIC DISEASE AND TREATMENT (2020)
Successful treatment of clozapine-nonresponsive refractory hallucinations and delusions with pimavanserin, a serotonin 5HT-2A receptor inverse agonist
Henry A. Nasrallah et al.
SCHIZOPHRENIA RESEARCH (2019)
Hypofunctional Dopamine Uptake and Antipsychotic Treatment-Resistant Schizophrenia
Davide Amato et al.
FRONTIERS IN PSYCHIATRY (2019)
Transdermal Delivery of Antipsychotics: Rationale and Current Status
Angela Abruzzo et al.
CNS DRUGS (2019)
Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities
Amanda Krogmann et al.
CNS SPECTRUMS (2019)
Clinical Course, Neurobiology and Therapeutic Approaches to Treatment Resistant Schizophrenia. Toward an Integrated View
Cheryl Cheuk-Yan Leung et al.
FRONTIERS IN PSYCHIATRY (2019)
Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia
Hiroyoshi Takeuchi et al.
NEUROPSYCHOPHARMACOLOGY (2019)
Reconsidering the Latent Structure of Negative Symptoms in Schizophrenia: A Review of Evidence Supporting the 5 Consensus Domains
Gregory P. Strauss et al.
SCHIZOPHRENIA BULLETIN (2019)
Antipsychotic Drug Responsiveness and Dopamine Receptor Signaling; Old Players and New Prospects
Antonio Rampino et al.
FRONTIERS IN PSYCHIATRY (2019)
Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia
William F. Martin et al.
AMERICAN JOURNAL OF PSYCHIATRY (2019)
Cognitive impairment in psychotic illness: prevalence, profile of impairment developmental course, and treatment considerations
Amanda McCleery et al.
DIALOGUES IN CLINICAL NEUROSCIENCE (2019)
Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study
Clive Ballard et al.
LANCET NEUROLOGY (2018)
Dopamine, the antipsychotic molecule: A perspective on mechanisms underlying antipsychotic response variability
Davide Amato et al.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2018)
Increasing expectations and knowledge require a more subtle use of prophylactic antipsychotics
Robin M. Murray et al.
WORLD PSYCHIATRY (2018)
Comparison of Early Intervention Services vs Treatment as Usual for Early-Phase Psychosis A Systematic Review, Meta-analysis, and Meta-regression
Christoph U. Correll et al.
JAMA PSYCHIATRY (2018)
The Latent Structure of Negative Symptoms in Schizophrenia
Gregory P. Strauss et al.
JAMA PSYCHIATRY (2018)
Systemic neurotransmitter responses to clinically approved and experimental neuropsychiatric drugs
Hamid R. Noori et al.
NATURE COMMUNICATIONS (2018)
Negative symptoms of psychosis: A life course approach and implications for prevention and treatment
John Lyne et al.
EARLY INTERVENTION IN PSYCHIATRY (2018)
Clozapine as a Model for Antipsychotic Development
Frederick C. Nucifora et al.
NEUROTHERAPEUTICS (2017)
Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors
A. Demjaha et al.
PSYCHOLOGICAL MEDICINE (2017)
Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy
Guy Chouinard et al.
PSYCHOTHERAPY AND PSYCHOSOMATICS (2017)
Update on the treatment of Parkinson's disease psychosis: role of pimavanserin
Brianna L. Combs et al.
NEUROPSYCHIATRIC DISEASE AND TREATMENT (2017)
Guidelines for the Pharmacotherapy of Schizophrenia in Adults
Gary Remington et al.
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE (2017)
Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology
Oliver D. Howes et al.
AMERICAN JOURNAL OF PSYCHIATRY (2017)
Clozapine V. first-and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis
Dan Siskind et al.
BRITISH JOURNAL OF PSYCHIATRY (2016)
Determination of Adherence Profiles in Schizophrenia Using Self-Reported Adherence: Results From the FACE-SZ Dataset
David Misdrahi et al.
JOURNAL OF CLINICAL PSYCHIATRY (2016)
Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses
J. Lally et al.
PSYCHOLOGICAL MEDICINE (2016)
Metabolic issues in patients affected by schizophrenia: clinical characteristics and medical management
Antonio Ventriglio et al.
FRONTIERS IN NEUROSCIENCE (2015)
Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial
Jeffrey Cummings et al.
LANCET (2014)
Science and Recovery in Schizophrenia
Jeffrey A. Lieberman et al.
PSYCHIATRIC SERVICES (2014)
Second-Generation Antipsychotics and Extrapyramidal Adverse Effects
Nevena Divac et al.
BIOMED RESEARCH INTERNATIONAL (2014)
Antipsychotic response in first-episode schizophrenia: efficacy of high doses and switching
Ofer Agid et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2013)
Schizophrenia Past Clozapine What Works?
Feras Ali Mustafa
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2013)
Predictors of early stable symptomatic remission after an exacerbation of schizophrenia: The significance of symptoms, neuropsychological performance and cognitive biases
Christina Andreou et al.
PSYCHIATRY RESEARCH (2013)
Symptom Domains and Neurocognitive Functioning Can Help Differentiate Social Cognitive Processes in Schizophrenia: A Meta-Analysis
Joseph Ventura et al.
SCHIZOPHRENIA BULLETIN (2013)
Using Treatment Response to Subtype Schizophrenia: Proposal for a New Paradigm in Classification
Saeed Farooq et al.
SCHIZOPHRENIA BULLETIN (2013)
Clinical symptoms, mainly negative symptoms, mediate the influence of neurocognition and social cognition on functional outcome of schizophrenia
Chieh-Hsin Lin et al.
SCHIZOPHRENIA RESEARCH (2013)
Schizophrenia Is a Cognitive Illness Time for a Change in Focus
Rene S. Kahn et al.
JAMA PSYCHIATRY (2013)
Clozapine and tardive movement disorders: A review
Nandita Hazari et al.
ASIAN JOURNAL OF PSYCHIATRY (2013)
Another view of the history of antipsychotic drug discovery and development
W. T. Carpenter et al.
MOLECULAR PSYCHIATRY (2012)
Time course of improvement with antipsychotic medication in treatment-resistant schizophrenia
Takefumi Suzuki et al.
BRITISH JOURNAL OF PSYCHIATRY (2011)
Serotonin 2A receptor antagonists for treatment of schizophrenia
Bjorn H. Ebdrup et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2011)
An Algorithm-Based Approach to First-Episode Schizophrenia: Response Rates Over 3 Prospective Antipsychotic Trials With a Retrospective Data Analysis
Ofer Agid et al.
JOURNAL OF CLINICAL PSYCHIATRY (2011)
A Multicenter, Inpatient, Phase 2, Double-Blind, Placebo-Controlled Dose-Ranging Study of LY2140023 Monohydrate in Patients With DSM-IV Schizophrenia
Bruce J. Kinon et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2011)
Transition to Adulthood: The Critical Period for Pre-emptive, Disease-modifying Care for Schizophrenia and Related Disorders
Patrick McGorry
SCHIZOPHRENIA BULLETIN (2011)
From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics
C. U. Correll
EUROPEAN PSYCHIATRY (2010)
Cariprazine (RGH-188), a Dopamine D3 Receptor-Preferring, D3/D2 Dopamine Receptor Antagonist-Partial Agonist Antipsychotic Candidate: In Vitro and Neurochemical Profile
Bela Kiss et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
Antipsychotic Dosing: How Much but also How Often?
Gary Remington et al.
SCHIZOPHRENIA BULLETIN (2010)
Non-Therapeutic Risk Factors for Onset of Tardive Dyskinesia in Schizophrenia: A Meta-Analysis
Diederik E. Tenback et al.
MOVEMENT DISORDERS (2009)
The Dopamine Hypothesis of Schizophrenia: Version III - The Final Common Pathway
Oliver D. Howes et al.
SCHIZOPHRENIA BULLETIN (2009)
Motivational deficits as the central link to functioning in schizophrenia: A pilot study
G. Foussias et al.
SCHIZOPHRENIA RESEARCH (2009)
Schizophrenia, just the facts 4. Clinical features and conceptualization
Rajiv Tandon et al.
SCHIZOPHRENIA RESEARCH (2009)
Symptoms as mediators of the relationship between neurocognition and functional outcome in schizophrenia: A meta-analysis
Joseph Ventura et al.
SCHIZOPHRENIA RESEARCH (2009)
Tardive dyskinesia and new antipsychotics
Christoph U. Correll et al.
CURRENT OPINION IN PSYCHIATRY (2008)
Are second generation antipsychotics a distinct class?
Caroline Bonham et al.
JOURNAL OF PSYCHIATRIC PRACTICE (2008)
Dose-Occupancy Study of Striatal and Extrastriatal Dopamine D2 Receptors by Aripiprazole in Schizophrenia with PET and [18F] Fallypride
Lawrence S. Kegeles et al.
NEUROPSYCHOPHARMACOLOGY (2008)
Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial
Sandeep T. Patil et al.
NATURE MEDICINE (2007)
Identification and treatment of the prodromal phase of psychotic disorders: perspectives from the PACE Clinic
Alison R. Yung
EARLY INTERVENTION IN PSYCHIATRY (2007)
The history of clozapine and its emergence in the US market: a review and analysis
John Crilly
HISTORY OF PSYCHIATRY (2007)
The dopamine stabilizers (S)-(-)-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonyl-phenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor side effects in the rat
Sridhar Natesan et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Phenotype of schizophrenia: a review and formulation
CA Tamminga et al.
MOLECULAR PSYCHIATRY (2005)
Consensus on the use of substituted benzamides in psychiatric patients
G Racagni et al.
NEUROPSYCHOBIOLOGY (2004)
Dopamine partial agonists - A new class of antipsychotic
JA Lieberman
CNS DRUGS (2004)
Atypical antipsychotics: Mechanism of action
P Seeman
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE (2002)
The early stages of schizophrenia: Speculations on pathogenesis, pathophysiology, and therapeutic approaches
JA Lieberman et al.
BIOLOGICAL PSYCHIATRY (2001)
Dopamine D2 receptors and their role in atypical antipsychotic action:: Still necessary and may even be sufficient
S Kapur et al.
BIOLOGICAL PSYCHIATRY (2001)
Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics?:: A new hypothesis
S Kapur et al.
AMERICAN JOURNAL OF PSYCHIATRY (2001)
Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment
PD Harvey et al.
AMERICAN JOURNAL OF PSYCHIATRY (2001)
Atypical antipsychotics: New directions and new challenges in the treatment of schizophrenia
S Kapur et al.
ANNUAL REVIEW OF MEDICINE (2001)
A positron emission tomography study of quetiapine in schizophrenia -: A preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy
S Kapur et al.
ARCHIVES OF GENERAL PSYCHIATRY (2000)
Neurocognitive deficits and functional outcome in schizophrenia: Are we measuring the right stuff?
MF Green et al.
SCHIZOPHRENIA BULLETIN (2000)
Atypical antipsychotics: are some more atypical than others?
G Remington et al.
PSYCHOPHARMACOLOGY (2000)
Share Paper
